ヒト人工多能性幹細胞由来心筋細胞における微小電極アレイおよびパッチクランプ記録の技術的応用

Executive Industry Relevance

Human iPSC-derived cardiomyocytes (hiPSC-CMs) enable predictive, human-relevant cardiac safety assessment early in drug discovery, addressing the translational gap left by animal models. Integrating microelectrode array and patch clamp recordings with hiPSC-CMs provides quantitative, mechanistic insights into drug-induced cardiotoxicity. This approach supports risk-adjusted portfolio decisions and enhances confidence in preclinical cardiac liability screening.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of cardiac electrophysiological pathways in a human cellular context.
• Supports mechanistic de-risking by quantifying drug effects on action potentials and field potentials.
• Facilitates functional target validation for cardiac safety liabilities.
• Improves predictive confidence for candidate triage based on human-specific data.

Screening & Assay Development

• Establishes validated, reproducible hiPSC-CM assays for compound screening.
• Delivers quantitative outputs such as beat period, field potential duration, and spike amplitude.
• Enables scalable, high-content screening using microelectrode arrays.
• Supports standardization of cardiac safety assays across discovery teams.

Translational & Preclinical Research

• Aligns preclinical cardiac safety models with human disease relevance.
• Provides continuity from early discovery through preclinical validation using the same cell platform.
• Reduces translational risk by leveraging patient- or disease-specific hiPSC-CMs.
• Enables assessment of drug-induced cardiotoxicity in genetically diverse backgrounds.

Pipeline & Workflow Integration

Microelectrode array and patch clamp recordings on hiPSC-CMs integrate into the discovery-to-preclinical continuum, bridging early safety assessment and translational research.

• Discovery Biology: Supports hypothesis testing and mechanistic clarification of cardiac drug effects.
• Screening: Provides reproducible, quantitative readouts for compound prioritization.
• Analytics: Generates actionable metrics such as action potential duration and calcium transient parameters.
• Translational Research: Maintains model continuity for biomarker alignment and disease modeling.
• Enterprise Reuse: Establishes a reusable, standardized platform for cardiac safety evaluation across programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac safety assessment.
• Operational Value: Delivers standardized, scalable, and reproducible functional assays.
• Strategic Value: Enables earlier go/no-go decisions and reduces late-stage attrition due to cardiac liabilities.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of drug candidates.

Implementation Considerations

• Requires expertise in hiPSC-CM culture and electrophysiological recording techniques.
• Needs access to microelectrode array and patch clamp instrumentation with analytical software.
• Demands cross-team standardization of assay protocols and data analysis.
• Adaptation may be needed for different hiPSC-CM lines or disease models.
• Dependent on high-purity, well-beating hiPSC-CM preparations for reliable outputs.

Biopharma FAQs